NMN and Endothelial Function: How NAD+ Supports the Lining of Your Blood Vessels

The relationship between NMN and endothelial function has emerged as one of the most clinically relevant questions in NAD+ research. Your endothelium—the single-cell-thick lining of your blood vessels—regulates vascular tone, blood clotting, and immune cell trafficking. When it dysfunctions, the downstream consequences include hypertension, atherosclerosis, and impaired tissue perfusion. Understanding whether NMN (nicotinamide mononucleotide) can support this lining through NAD+ replenishment requires careful parsing of preclinical models, human biomarker studies, and the mechanistic pathways that connect cellular energy metabolism to vascular health.

What the Research Landscape Shows for NMN and Endothelial Function

Direct human trials examining NMN and endothelial function as a primary endpoint remain limited. Most of the evidence base consists of small-scale human studies measuring NAD+ metabolite levels and systemic metabolic parameters, combined with mechanistic work in animal models and cell culture systems.

The landmark human trial by Yoshino et al. (2021) randomized 25 postmenopausal women with prediabetes to receive 250 mg NMN daily for 10 weeks. While the primary outcome was muscle insulin sensitivity, the study reported improvements in markers of tissue NAD+ biosynthesis. Notably, this was a small, single-center trial with no direct vascular endpoint measurements such as flow-mediated dilation (FMD) or pulse wave velocity.

Igarashi et al. (2022) conducted a randomized controlled trial in 108 healthy older adults with mild sleep disturbance, administering 250 mg NMN daily for 12 weeks. Blood NAD+ levels rose significantly, and subjective fatigue scores improved. Again, no dedicated vascular function assessments were included, leaving the endothelial question unanswered at the clinical level.

Fukamizu et al. (2022) examined 11 healthy Japanese men receiving 125–500 mg NMN daily for up to 12 weeks. The study confirmed dose-dependent increases in blood NMN and NAD+ metabolites but did not measure endothelial-dependent vasodilation or nitric oxide bioavailability.

The strongest preclinical evidence comes from Mills et al. (2016), who administered NMN to aged mice for 12 months. Treated animals showed improved blood flow, enhanced endurance, and restored capillary density in skeletal muscle. These vascular benefits were linked to restored endothelial NAD+ levels and improved SIRT1 activity in the vessel wall. However, murine vascular biology differs substantially from humans in terms of lifespan, shear stress patterns, and plaque development—caution is warranted when extrapolating these findings.

Study	Population	NMN Dose	Duration	Endothelial-Relevant Findings
Yoshino et al. (2021)	25 prediabetic women	250 mg/day	10 weeks	Improved tissue NAD+; no direct vascular measures
Igarashi et al. (2022)	108 older adults	250 mg/day	12 weeks	Elevated blood NAD+; reduced fatigue; no vascular endpoints
Fukamizu et al. (2022)	11 healthy men	125–500 mg/day	Up to 12 weeks	Dose-dependent NAD+ metabolite increases; no FMD or NO data
Mills et al. (2016)	Aged mice	~300–500 mg/kg/day	12 months	Restored capillary density, blood flow, endothelial SIRT1

How NAD+ Supports Endothelial Cell Biology

The molecular rationale linking NMN and endothelial function rests on NAD+ as a required cofactor for sirtuins, poly(ADP-ribose) polymerases (PARPs), and CD38. In endothelial cells, NAD+ depletion with aging or metabolic stress impairs these enzymatic networks, contributing to oxidative stress, inflammation, and reduced nitric oxide (NO) bioavailability.

SIRT1, an NAD+-dependent deacetylase, directly deacetylates and activates endothelial nitric oxide synthase (eNOS), the enzyme responsible for producing NO from L-arginine. NO is the primary endothelium-derived relaxing factor; it diffuses into vascular smooth muscle, activates soluble guanylate cyclase, and triggers vasodilation. Mills et al. (2016) demonstrated that NMN restored SIRT1 activity in aged mouse endothelium, correlating with improved vascular compliance and tissue perfusion.

Beyond SIRT1, NAD+ serves as the electron acceptor in glycolysis and oxidative phosphorylation. Endothelial cells are highly glycolytic under resting conditions, but mitochondrial function becomes critical during angiogenesis and shear stress adaptation. Garten et al. (2015) reviewed the broader physiology of NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in NAD+ salvage. NAMPT expression declines with age in multiple tissues, including the vasculature, creating a plausible mechanism for NAD+ depletion and endothelial dysfunction.

CD38, a membrane-bound NADase, increases with aging and further depletes cellular NAD+ pools. Preclinical data suggest that inhibiting CD38 or supplementing NMN can counteract this age-related drain, preserving the NAD+ available for sirtuin-mediated vascular protection. However, these experiments have been performed primarily in rodents and cell lines; human endothelial CD38 dynamics and their response to oral NMN remain understudied.

NMN Dosage, Form, and Timing for Vascular Support

For readers considering NMN and endothelial function as a personal health strategy, understanding the dose-response landscape from existing human trials is essential. No study has yet identified a vascular-specific NMN dose, but the pharmacokinetic and tolerability data provide a reasonable framework.

The 250 mg daily dose used in Yoshino et al. (2021) and Igarashi et al. (2022) represents the most common regimen in published human RCTs. Fukamizu et al. (2022) tested 125 mg, 250 mg, and 500 mg, finding dose-dependent increases in plasma NMN and NAD+ metabolites without serious adverse events. No study has reported improved vascular outcomes at higher versus lower doses.

NMN is orally bioavailable and appears in plasma within minutes of ingestion, with a half-life of approximately 2–3 hours based on pharmacokinetic substudies. Whether divided dosing (e.g., 125 mg twice daily) provides superior endothelial NAD+ exposure compared to single daily dosing is unknown. Most trials have used once-daily administration, typically in the morning.

PEPAX NMN provides 500 mg per capsule, a dose that aligns with the upper range tested in human safety and pharmacokinetic studies. Individuals interested in vascular health should recognize that this exceeds the 250 mg dose used in most efficacy trials to date, and that optimal dosing for endothelial outcomes remains undefined.

Dose	Study Reference	Population	Key Outcome
125 mg/day	Fukamizu et al. (2022)	Healthy men	Detectable plasma NMN increase
250 mg/day	Yoshino et al. (2021)	Prediabetic women	Improved muscle insulin sensitivity
250 mg/day	Igarashi et al. (2022)	Older adults	Elevated blood NAD+, reduced fatigue
500 mg/day	Fukamizu et al. (2022)	Healthy men	Higher NAD+ metabolite levels, well tolerated

Who Benefits Most From NMN and Endothelial Function Support

The populations in whom NMN and endothelial function supplementation is most theoretically justified are those with established NAD+ depletion risk factors: aging, metabolic syndrome, prediabetes, and sedentary lifestyle. These conditions are associated with reduced NAMPT expression, elevated CD38 activity, and impaired endothelium-dependent vasodilation in independent studies.

Postmenopausal women represent a particularly relevant group. Estrogen exerts direct protective effects on eNOS expression and NO bioavailability; its decline after menopause accelerates endothelial dysfunction. Yoshino et al. (2021) specifically enrolled this demographic and observed metabolic improvements, though vascular endpoints were not measured. Whether NMN can partially compensate for estrogen-related endothelial decline is a testable hypothesis that has not yet been directly examined.

Older adults with mild sleep disturbance, as studied by Igarashi et al. (2022), may also represent a reasonable target population. Sleep fragmentation is associated with elevated sympathetic tone, oxidative stress, and endothelial dysfunction. The observed reductions in fatigue and improvements in NAD+ status in this cohort provide indirect support for further vascular investigation.

Individuals already optimizing vascular health through exercise, dietary nitrate intake, or hydrogen water and nitric oxide support may view NMN as a complementary strategy rather than a standalone intervention. The evidence does not support replacing proven vascular therapies—such as statins, ACE inhibitors, or lifestyle modification—with NMN.

Importantly, no human study has demonstrated that NMN reverses established endothelial dysfunction in patients with cardiovascular disease. The existing trials were conducted in healthy or metabolically at-risk populations without diagnosed vascular pathology. People with active cardiovascular conditions should consult their physician before adding NMN to their regimen.

Practical Takeaways on NMN and Endothelial Function

• Evidence quality is preliminary. Most human studies on NMN and endothelial function are small-scale, short-duration, and lack direct vascular endpoints such as flow-mediated dilation or arterial stiffness measures.
• Mechanistic rationale is strong but preclinical. NAD+-SIRT1-eNOS signaling is well characterized in cell and animal models; human endothelial confirmation is pending.
• 250 mg daily is the most studied dose. Two RCTs used this regimen successfully; 500 mg was well tolerated in a pharmacokinetic study but lacks additional efficacy data.
• Morning dosing is standard. All major trials administered NMN in the morning; no data support evening administration for vascular benefit.
• Consider NMN alongside proven vascular strategies. NMN and heart health should be viewed as complementary to exercise, blood pressure control, and dietary patterns such as the Mediterranean diet—not as replacements.
• Monitor for interactions. NMN has not been studied extensively alongside antihypertensive or anticoagulant medications; discuss with a clinician if you are on cardiovascular drug therapy.

How NMN Compares to Other Vascular Support Strategies

Readers evaluating NMN and endothelial function often ask how it compares to other supplements with vascular claims. The honest answer is that the comparative evidence is essentially nonexistent—no head-to-head RCTs have pitted NMN against L-arginine, beetroot extract, or CoQ10 for endothelial outcomes.

What distinguishes NMN is its position upstream in cellular metabolism. Rather than providing substrate for NO synthesis (like L-arginine) or dietary nitrate (like beetroot), NMN attempts to restore the NAD+ cofactor pool that fuels sirtuin enzymes and mitochondrial ATP production. This mechanistic difference suggests that NMN might offer broader cellular benefits—potentially influencing exercise capacity and metabolic health simultaneously—though at the cost of less direct and immediate vascular action.

For those interested in longevity science, the question of whether NMN extends lifespan remains unresolved in humans. How strong is the evidence that NMN extends life? Currently, it is based entirely on animal data and theoretical inference; no human mortality or morbidity trial has been completed.

The Bottom Line on NMN and Endothelial Function

The connection between NMN and endothelial function is biologically plausible, mechanistically grounded in NAD+-SIRT1-eNOS signaling, and supported by encouraging preclinical data showing restored vascular perfusion in aged mice. However, human trials have not yet directly measured endothelial outcomes, and most published studies are small, short, and focused on metabolic rather than vascular endpoints. For now, NMN should be considered a promising but unproven candidate for vascular support—best suited to informed adults who understand the evidence limitations and integrate it within a broader cardiovascular health strategy.

---

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels in healthy subjects with mild sleep disturbance." NPJ Aging. 2022;8(1):5. [Source]
3. Fukamizu Y, et al. "Effects of orally administered nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Scientific Reports. 2022;12:6134. [Source]
4. Mills KF, et al. "Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice." Cell Metabolism. 2016;24(6):795–806. [Source]
5. Garten A, et al. "Physiological and pathophysiological roles of NAMPT and NAD metabolism." Nature Reviews Endocrinology. 2015;11(9):535–546. [Source]

---

---